Harmony Biosciences (HRMY) Tops Q4 EPS by 28c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Wall St rebounds after Fed's first rate hike in years as oil, Treasury yields dip
- Oil falls 2% to one-week low as Middle East supply disruption fears ease
- The Fed is hiking. Why isn't UBS worried about stocks?
- Wall Street on Fed rate hike: 'As hawkish as it gets'
- RBC bullish on Kraft Heinz, sees return to growth in 2027
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Shipping stocks on fire — but cracks are forming in the rate rally
- Paradium AI (PAAI) Halted, News Pending
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
Harmony Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Business Updates
February 28, 2022 7:30 AM ESTWAKIX® (pitolisant) Net Revenue Increased 62% Year-over-Year to $91.2 Million for Fourth Quarter 2021 and 91% to $305.4 Million for Full Year
Achieved First Full Year of Profitability and Net income was $22.7 Million for the Fourth Quarter 2021
Average Number of Patients on WAKIX Increased to ~3,800
On Track to Initiate the Phase 3 Clinical Trial in Patients with Idiopathic Hypersomnia First Half of This Year
 Year-End 2021 Cash and Cash Equivalents of Approximately $234 Million
Conference Call and Webcast to be Held Today at 8:30 a.m. ETÂ
... More